Data Pseudonymization and POPIA
Navigating the realm of data privacy is as intricate as deciphering the myriad forms of a shape-shifting deity.
Professional Regulation
-
Read more: Data Pseudonymization and POPIA -
Read more: We May Not ‘Own’ Our Bodies. Should We? We May Not ‘Own’ Our Bodies. Should We?
The property law approach to ownership does not draw hard lines with respect to biological materials like tissue.
-
Read more: What’s on the Horizon for Health and Biotech with the AI Executive Order What’s on the Horizon for Health and Biotech with the AI Executive Order
Biden’s Executive Order on artificial intelligence is an important development for health care practitioners, researchers, and legal experts.
-
Read more: The Privatization of Cancer The Privatization of Cancer
In my forthcoming article, I argue that our cancer regulatory regimes inadequately protect the public.
-
Read more: Harmonizing Africa’s Data Governance: Challenges and Solutions Harmonizing Africa’s Data Governance: Challenges and Solutions
This article delves into two critical concerns with establishing a single data market across Africa: data privacy and data ownership.
-
Read more: Protecting Consumer Privacy in DTC Tissue Testing Protecting Consumer Privacy in DTC Tissue Testing
The privatization of next-generation medical technologies, especially in regenerative and precision medicine, further muddies the data-protection waters.
-
Read more: Why We Should Care About the Move from Saliva to Living Cells in Precision Medicine Why We Should Care About the Move from Saliva to Living Cells in Precision Medicine
Could a corporate, direct-to-consumer cell-based testing service be the next 23andme? And what would that mean for patients?
-
Read more: Context Matters: Affirmative Action, Public Health, and the Use of Population-Level Data Context Matters: Affirmative Action, Public Health, and the Use of Population-Level Data
The Court’s rejection of group-level data in SFFA portends troubling implications for health equity and health policy.
-
Read more: Reasonable Pricing Clauses: A First Step Toward Ensuring Taxpayers a Fair Return on their Public R&D Investment Reasonable Pricing Clauses: A First Step Toward Ensuring Taxpayers a Fair Return on their Public R&D Investment
Reasonable pricing clauses are needed to ensure that American taxpayers receive a fairer return on their investment for essential therapies.
-
Read more: On Siri and Recognitive Violence On Siri and Recognitive Violence
What does it mean when our devices recognize us more accurately when we utter the dialect of consumerism?
